Valneva shows an extreme risk/reward asymmetry (12.53x, 98.5% upside) at a deeply discounted valuation and small-cap institutional-constraint edge, but a quality score below the engine's floor, declining revenue, and a confirmed technical downtrend with a hard death-cross block argue the discount reflects real fundamental weakness.
Thesis pillars
- Deep Value Extreme Asymmetry→Stable
- Quality Floor Breach Cash Burn→Stable
- Declining Revenue Growth Concern→Stable
- +2 more pillars — see the Why tab for full reasoning
Valneva SE (VALN) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.31: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against... Read more
Sell if holding. Engine safety override at $5.31: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Score 4.8/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -88.3%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.31: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 12.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $4.93. Score 4.8/10, moderate confidence.
Take-profit target: $10.37 (+95.7% upside). Prior stop was $4.93. Stop-loss: $4.93.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.8%), Material insider selling (7 sells, 0.07% of cap).
Valneva SE trades at a P/E of N/A (forward 5.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover VALN with a consensus score of 4.1/5. Average price target: $12.
What does Valneva SE do?Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for...
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.